None listed
Conditions
Interventions
BMS-931699 (active) is administered subcutaneously, is formulated at 12.5 mg/mL and is provided as a liquid in single-use vials. Four treatments will be administered along with placebo treatment: 12.5
Sponsors
BRISTOL MYERS SQUIBB COMPANY,
Eligibility
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) SLE defined by 4 of 11 classification criteria of ACR for SLE (sequentially or coincidently). 2)Subjects must have elevated ANA > to 1:80 via immunofluorescent assay and/or positive anti-dsDNA or anti-Sm above the normal level (all determined by the central laboratory). 3)Subjects must have a SLEDAI greater or equal to 6. At least 4 of the points must be attributable to clinical criteria. Must be confirmed by External Adjudication Committee. 4)Subjects must have at least one of the following manifestations of SLE, which must be confirmed by the External Adjudication committee: BILAG A or B score in the Mucocutaneous body system or BILAG A or B score in the Musculoskeletal body system due to active polyarthritis as defined in protocol. 5) Subjects must be currently receiving at least one of the following: (1)Administration for a minimum of 12 weeks, and a stable dose for at least 56 days (8 weeks) prior to signing consent, of the following steroid sparing agents are permitted: azathioprine (AZA), chloroquine, hydroxychloroquine or methotrexate (MTX) and, (2)Prednisone (or prednisone-equivalent) cannot exceed 30mg/day at screening for a subject to be eligible and must be stable at a maximum of 10 mg/day for at least 5 days prior to Day 1.
Exclusion criteria
Exclusion criteria: 1) Sujetos con LES inducida por farmacos, en lugar de LES idiopatica. 2) Sujetos con otra enfermedad autoinmune. 3) Sujetos con sindrome de anticuerpos antifosfolipido primario como rasgo unico o principal de su LES o sindrome simlar a LES. 4) Sujetos con antecedentes o riesgo para la tuberculosis (TB). 5) Los sujetos con manifestaciones neuropsiquiatricas del lupus activa o inestables y sujetos con nefritis lupica grave activa (OMS clase III, IV). Nota: Se permite re-enrolamientos de pacientes
Countries
Argentina, Brazil, Canada, Chile, France, Germany, Hungary, Italy, Korea South, Mexico, Peru, Poland, Romania, South Africa, Spain, Taiwan, United States
Contacts
Public ContactMarina Ordonez
BRISTOL MYERS SQUIBB PERU S.A.
Outcome results
None listed